Barclays
CTKB icon

Barclays’s Cytek Biosciences CTKB Stock Holding History

Barclays’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.9K Sell
19,606
-4,537
-19% -$19.4K ﹤0.01% 4103
2026
Q1 		$106K Sell
24,143
-159,096
-87% -$751K ﹤0.01% 3999
2025
Q4 		$925K Buy
183,239
+17,667
+11% +$82K ﹤0.01% 3482
2025
Q3 		$575K Sell
165,572
-222,336
-57% -$835K ﹤0.01% 3722
2025
Q2 		$1.32M Buy
387,908
+235,045
+154% +$783K ﹤0.01% 3148
2025
Q1 		$613K Sell
152,863
-62,561
-29% -$324K ﹤0.01% 3395
2024
Q4 		$1.4M Buy
215,424
+14,065
+7% +$83.8K ﹤0.01% 3153
2024
Q3 		$1.12M Buy
201,359
+154,915
+334% +$878K ﹤0.01% 3288
2024
Q2 		$259K Sell
46,444
-60,174
-56% -$361K ﹤0.01% 3433
2024
Q1 		$715K Sell
106,618
-82,725
-44% -$654K ﹤0.01% 3356
2023
Q4 		$1.73M Buy
189,343
+140,164
+285% +$882K ﹤0.01% 3031
2023
Q3 		$271K Buy
49,179
+411
+0.8% +$3.3K ﹤0.01% 3136
2023
Q2 		$416K Sell
48,768
-9,021
-16% -$80.9K ﹤0.01% 2870
2023
Q1 		$531K Buy
57,789
+27,130
+88% +$292K ﹤0.01% 3229
2022
Q4 		$313K Buy
30,659
+25,818
+533% +$347K ﹤0.01% 3597
2022
Q3 		$71K Sell
4,841
-12,810
-73% -$166K ﹤0.01% 3667
2022
Q2 		$189K Sell
17,651
-15,005
-46% -$149K ﹤0.01% 3459
2022
Q1 		$351K Buy
+32,656
New +$441K ﹤0.01% 3114

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Barclays's CTKB Position: Q2 2026 in Review

Barclays reduced its Cytek Biosciences (CTKB) stake by 19% in Q2 2026, selling an estimated $19.4K and leaving 19,606 shares worth $86.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4103.

Barclays first reported a position in CTKB in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.73M in Q4 2023. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Barclays held 19,606 shares of Cytek Biosciences worth $86.9K as of Q2 2026.
  • Barclays sold 4,537 Cytek Biosciences shares in Q2 2026, an estimated $19.4K.
  • Cytek Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4103 holding.
  • Barclays first reported a position in Cytek Biosciences in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Cytek Biosciences position peaked at $1.73M in Q4 2023.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.